Paper39997697
From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension.
Porada M and 1 other. Metabolites, 2025. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension. Papers, record 39997697. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39997697
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| BNW-1-157/N/4/K | Medical University of Silesia | PubMed |
Source PubMed
References359
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26656007 | Associations between the tumor necrosis factor-α gene and interleukin-10 gene polymorphisms and risk of alcoholic liver disease: A meta-analysis. | Clin Res Hepatol Gastroenterol | 2016 | https://conductscience.org/library/papers/26656007 | PubMed |
| 2 | 38906512 | Targeting 5-Hydroxytryptamine Receptor 1A in the Portal Vein to Decrease Portal Hypertension. | Gastroenterology | 2024 | https://conductscience.org/library/papers/38906512 | PubMed |
| 3 | 19157625 | Angiogenesis in liver disease. | J Hepatol | 2009 | https://conductscience.org/library/papers/19157625 | PubMed |
| 4 | 34165199 | Randomised clinical study: acute effects of metformin versus placebo on portal pressure in patients with cirrhosis and portal hypertension. | Aliment Pharmacol Ther | 2021 | https://conductscience.org/library/papers/34165199 | PubMed |
| 5 | 33804385 | PNPLA3 and SERPINA1 Variants Are Associated with Severity of Fatty Liver Disease at First Referral to a Tertiary Center. | J Pers Med | 2021 | https://conductscience.org/library/papers/33804385 | PubMed |
| 6 | 4924592 | Hepatic fibrosis. Correlation of biochemical and morphologic investigations. | Am J Med | 1970 | https://conductscience.org/library/papers/4924592 | PubMed |
| 7 | 26573697 | How to effectively manage the event of bleeding complications when using anticoagulants. | Expert Rev Hematol | 2016 | https://conductscience.org/library/papers/26573697 | PubMed |
| 8 | 24134058 | Beta-blockers in portal hypertension: new developments and controversies. | Liver Int | 2014 | https://conductscience.org/library/papers/24134058 | PubMed |
| 9 | 22806357 | Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. | Hepatology | 2012 | https://conductscience.org/library/papers/22806357 | PubMed |
| 10 | 32302598 | Statins and PCSK9 inhibitors: A new lipid-lowering therapy. | Eur J Pharmacol | 2020 | https://conductscience.org/library/papers/32302598 | PubMed |
| 11 | 31893957 | PCSK9 inhibitors for treating hypercholesterolemia. | Expert Opin Pharmacother | 2020 | https://conductscience.org/library/papers/31893957 | PubMed |
| 12 | 27332721 | Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease. | Dig Dis | 2016 | https://conductscience.org/library/papers/27332721 | PubMed |
| 13 | 14687169 | A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis. | Aliment Pharmacol Ther | 2004 | https://conductscience.org/library/papers/14687169 | PubMed |
| 14 | 31705824 | Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population. | Hepatology | 2020 | https://conductscience.org/library/papers/31705824 | PubMed |
| 15 | 17016424 | Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. | Nat Rev Drug Discov | 2006 | https://conductscience.org/library/papers/17016424 | PubMed |
| 16 | 26406236 | Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis. | PLoS One | 2015 | https://conductscience.org/library/papers/26406236 | PubMed |
| 17 | 17336417 | AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. | J Hepatol | 2007 | https://conductscience.org/library/papers/17336417 | PubMed |
| 18 | 25309079 | Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease. | World J Gastroenterol | 2014 | https://conductscience.org/library/papers/25309079 | PubMed |
| 19 | 26412302 | Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension. | Sci Rep | 2015 | https://conductscience.org/library/papers/26412302 | PubMed |
| 20 | 29331339 | Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis. | J Hepatol | 2018 | https://conductscience.org/library/papers/29331339 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42279197 | Longitudinal Inpatient Trajectories After Splenic Artery Embolization in Cirrhosis: Real-World Evidence from Kazakhstan. | J Clin Med | 2026 | https://conductscience.org/library/papers/42279197 | PubMed |
| 41278477 | Gut microbiome and its metabolites in liver cirrhosis: mechanisms and clinical implications. | Front Cell Infect Microbiol | 2025 | https://conductscience.org/library/papers/41278477 | PubMed |
| 41210055 | Liver Cirrhosis in Pregnancy and Its Fetal Outcomes: A Prospective Case Series. | Cureus | 2025 | https://conductscience.org/library/papers/41210055 | PubMed |
| 41105553 | Pharmacological Management for Prevention and Treatment of Posthepatectomy Liver Failure. | Dig Surg | 2025 | https://conductscience.org/library/papers/41105553 | PubMed |
| 40784797 | [Research progress on early-stage primary biliary cholangitis accompanied by portal hypertension]. | Zhonghua Gan Zang Bing Za Zhi | 2025 | https://conductscience.org/library/papers/40784797 | PubMed |
| 40591004 | TEAD4-mediated upregulation of LPAR3 augments hepatic stellate cell activation in portal hypertension. | Cell Biol Toxicol | 2025 | https://conductscience.org/library/papers/40591004 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39997697
GET https://conductscience.org/api/papers/v1/39997697/references?page=2